STUDY OF DRUGS IN PATIENTS OF PAINFUL DIABETIC NEUROPATHY

A RANDOMISED COMPARATIVE STUDY OF METHYLCOBALAMIN, METHYLCOBALAMIN PLUS PREGABALIN AND METHYLCOBALAMIN PLUS DULOXETINE IN PATIENTS OF PAINFUL DIABETIC NEUROPATHY

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2019/08/020810

Enrollment

100

Registered

2019-08-21

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E114- Type 2 diabetes mellitus with neurological complications

Interventions

Intervention1: methylcobalamin: methylcobalamin 1500mcg/day for 3 months Control Intervention1: methylcobalamin plus pregabalin: methylcobalamin plus pregabalin (150mg/day) daily for 3 months Control

Eligibility

Inclusion criteria

Inclusion criteria: patients more than 18 years of age with type 2 diabetes mellitus with signs and symptoms of painful diabetic neuropathy

Exclusion criteria

Exclusion criteria: type 1 diabetes mellitus other reasons known to cause neuropathy

Design outcomes

Primary

Measure	Time frame
1. To study the effect of methylcobalamin, combination of methylcobalamin with pregabalin and methylcobalamin with duloxetine in patients with painful diabetic neuropathy.Timepoint: outcome will be assessed at the end of three month period from the day of recruitment	—

Secondary

Measure	Time frame
2. To compare safety, tolerability and economic implications of all the three study groups.Timepoint: monthly for 3 months	—

Countries

India

Contacts

Public ContactChetna sharma

government medical college, amritsar

inderpalpharma@gmail.com9501004136

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026